<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01827631</url>
  </required_header>
  <id_info>
    <org_study_id>116416</org_study_id>
    <nct_id>NCT01827631</nct_id>
  </id_info>
  <brief_title>Single and Repeat Dose Pharmacokinetic Study of GSK1605786 in Healthy Chinese Subjects</brief_title>
  <official_title>Single and Repeat Dose Pharmacokinetic Study of GSK1605786 in Healthy Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, parallel group, single and repeat dose pharmacokinetic (PK) study in
      healthy male and female subjects. This study will confirm the PK and safety profile in
      Chinese subjects. GSK1605786 is currently in clinical development for the treatment of
      Crohn's disease. Subjects will receive one of two GSK1605786 doses (500 mg once daily or
      500mg twice daily) within 30 minutes after a meal. The study will consist of single and
      repeat dose sessions, with pre-dose and serial PK samples taken up to 72-h post-dose.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 27, 2013</start_date>
  <completion_date type="Actual">June 25, 2013</completion_date>
  <primary_completion_date type="Actual">June 14, 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>up to 72 hour post dose</time_frame>
    <description>maximum concentration after single dose and repeat dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-Ï„)</measure>
    <time_frame>up to 24 hour post last dose</time_frame>
    <description>area under the concentration time curve during steady state</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events (AEs)</measure>
    <time_frame>up to 21 days, from the first dose until the follow-up visit</time_frame>
    <description>AEs occur during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vital signs</measure>
    <time_frame>before each morning dose on Day 1 and 8-14, and on Day 17 prior to leaving the clinic</time_frame>
    <description>blood pressure, pulse rate, respiratory rate and temperature</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lab assessment</measure>
    <time_frame>Day 17 prior to leaving the clinic</time_frame>
    <description>Hematology/Clinical Chemistry/Urinalysis test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>GSK1605786 500 mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK1605786 500 mg is given once daily in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GSK1605786 500 mg twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK1605786 500 mg is given twice daily in the morning and in the evening</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK1605786 capsule</intervention_name>
    <description>Swedish Orange, size 0, hard gelatine capsules</description>
    <arm_group_label>GSK1605786 500 mg twice daily</arm_group_label>
    <arm_group_label>GSK1605786 500 mg once daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy as determined by a responsible and experienced physician, based on a medical
             evaluation including medical history, physical examination, laboratory tests and ECG

          -  Male or female between 18 and 45 years of age

          -  Body weight 50 kg (110lbs) for men and women, and body mass index (BMI) within the
             range 19 24 kg/m2

        Exclusion Criteria:

          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody
             result within 3 months of screening

          -  Current or chronic history of liver disease, or known hepatic or biliary

          -  A positive test for HIV antibody at screening

          -  Known coeliac disease and positive serologic testing for anti-tTG antibodies

          -  A positive pre-study drug/alcohol screen

          -  Lactating females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <link>
    <url>https://gsk-clinicalstudyregister.com/study/116416?search=study&amp;search_terms=116416#rs</url>
    <description>Results for study 116416 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2013</study_first_submitted>
  <study_first_submitted_qc>April 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2013</study_first_posted>
  <last_update_submitted>June 5, 2017</last_update_submitted>
  <last_update_submitted_qc>June 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy</keyword>
  <keyword>GSK1605786</keyword>
  <keyword>CCR9 receptor antagonist</keyword>
  <keyword>Chinese subjects</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>116416</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116416</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116416</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116416</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116416</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116416</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116416</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

